Sector
PharmaceuticalsOpen
₹2,314.7Prev. Close
₹2,300.6Turnover(Lac.)
₹8,856.6Day's High
₹2,314.7Day's Low
₹2,293.352 Week's High
₹3,054.852 Week's Low
₹1,901.05Book Value
₹353Face Value
₹1Mkt Cap (₹ Cr.)
95,237.16P/E
50.37EPS
45.65Divi. Yield
0The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.
Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.
The cumulative demand, including interest charges, is ₹183.11 crore.
The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.
The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 40.06 | 40.06 | 40.06 | 40.06 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 9,583.75 | 7,743.85 | 6,500.39 | 4,694.21 |
Net Worth | 9,623.81 | 7,783.91 | 6,540.45 | 4,734.27 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 12,207.44 | 10,260.44 | 8,749.43 | 7,781.56 | 6,214.43 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,207.44 | 10,260.44 | 8,749.43 | 7,781.56 | 6,214.43 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 553.56 | 296.41 | 140.99 | 210.48 | 182.63 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,662.5 | 93.09 | 3,98,685.5 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,636 | 79.71 | 1,76,074.69 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,499.1 | 24.58 | 1,21,022.9 | 1,485.4 | 1.07 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,317.9 | 20.56 | 1,09,971.43 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,165.5 | 56.22 | 1,07,116.56 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
RAMESH CHAND JUNEJA
Vice Chairman & M.D.
RAJEEV JUNEJA
Whole Time Director & CEO
SHEETAL ARORA
Independent Director
TILOKCHAND PUNAMCHAND OSTWAL
Independent Director
Bharat Anand
Whole-time Director
SATISH KUMAR SHARMA
Independent Director
Vivek Kalra
Independent Director
Vijaya Sampath
Company Sec. & Compli. Officer
Hitesh Kumar Jain
208 Okhla Industrial Estate,
Phase-III,
New Delhi - 110020
Tel: 91-11-47476600
Website: http://www.mankindpharma.com
Email: investors@mankindpharma.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Purs...
Read More
Reports by Mankind Pharma Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.